FDA Approves Lannett’s VELTANE 4 mg Oral Tablet (ANDA 084088)

On May 17, 1974, the U.S. Food and Drug Administration granted approval for ANDA 084088, covering VELTANE 4 mg oral tablets. The product, submitted by Lannett, contains brompheniramine maleate as the active ingredient and is marketed as a prescription medication. VELTANE is an oral tablet (route: oral) with a dosage form of tablet, and it is not designated as a reference drug. The original submission (submission number 1) received an approved status (AP).